Literature DB >> 668778

Output of 14CO2 in breath after oral administration of (14C-methyl) aminopyrine in hepatitis, cirrhosis and hepatic bilharziasis: its relationship to aminopyrine pharmacokinetics.

J Noordhoek, J Dees, E M Savenije-Chapel, J H Wilson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1978        PMID： 668778     DOI： 10.1007/BF00609987

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN： 0031-6970            Impact factor:   2.953


× No keyword cloud information.
  19 in total

1.  Metabolism and excretion of aminopyrine in man.

Authors:  T Goromaru; A Noda; K Matzuyama; S Iguchi
Journal:  Chem Pharm Bull (Tokyo)       Date:  1976-06       Impact factor: 1.645

2.  The fate of aminopyrine (pyramidon) in man and methods for the estimation of aminopyrine and its metabolites in biological material.

Authors:  B B BRODIE; J AXELROD
Journal:  J Pharmacol Exp Ther       Date:  1950-06       Impact factor: 4.030

Review 3.  Drug disposition and liver disease.

Authors:  G R Wilkinson; S Schenker
Journal:  Drug Metab Rev       Date:  1975       Impact factor: 4.518

4.  Evaluation of in vivo parameters of drug metabolizing enzyme activity in man after administration of clemastine, phenobarbital or placebo.

Authors:  A G Hildebrandt; I Roots; M Speck; K Saalfrank; H Kewitz
Journal:  Eur J Clin Pharmacol       Date:  1975-06-13       Impact factor: 2.953

5.  Assessment of aminopyrine metabolism in man by breath analysis after oral administration of 14C-aminopyrine. Effects of phenobarbital, disulfiram and portal cirrhosis.

Authors:  G W Hepner; E S Vesell
Journal:  N Engl J Med       Date:  1974-12-26       Impact factor: 91.245

6.  Clearance and biologic half-life as indices of intrinsic hepatic metabolism.

Authors:  D Perrier; M Gibaldi
Journal:  J Pharmacol Exp Ther       Date:  1974-10       Impact factor: 4.030

7.  Kinetics of CO2-HCO3 minus in normal adult males.

Authors:  H S Winchell; H Stahelin; N Kusubov; B Slanger; M Fish; M Pollycove; J H Lawrence
Journal:  J Nucl Med       Date:  1970-12       Impact factor: 10.057

Review 8.  Drug absorption.

Authors:  L Ther; D Winne
Journal:  Annu Rev Pharmacol       Date:  1971       Impact factor: 13.820

9.  Aminopyrine demethylation measured by breath analysis in cirrhosis.

Authors:  J Bircher; A Küpfer; I Gikalov; R Preisig
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

10.  Aminopyrine disposition: studies on breath, saliva, and urine of normal subjects and patients with liver disease.

Authors:  G W Hepner; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1976-12       Impact factor: 6.875
View more
  6 in total

1.  Impairment of hepatic drug metabolism in patients with acute viral hepatitis.

Authors:  A P Narang; D V Datta; N Nath; V S Mathur
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Oct-Dec       Impact factor: 2.441

2.  Effect of experimentally-induced hepatic cirrhosis on the pharmacokinetics of orally administered praziquantel in the rat.

Authors:  G O Kokwaro; G Taylor
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1990 Jul-Sep       Impact factor: 2.441

3.  Assessment of drug metabolism in hepatic disease: comparison of plasma kinetics of oral cyclobarbital and the intravenous aminopyrine breath test.

Authors:  U Breyer-Pfaff; H Seyfert; M Weber; E H Egberts
Journal:  Eur J Clin Pharmacol       Date:  1984       Impact factor: 2.953

4.  Interpretation of CO2 exhalation rate data from demethylation of aminopyrine and its metabolite monomethylaminoantipyrine.

Authors:  J C Rhodes; L J Aarons; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1982-09       Impact factor: 4.335

5.  [14C]Aminopyrine breath analysis and conventional biochemical tests as predictors of survival in cirrhosis.

Authors:  D A Henry; G Kitchingman; M J Langman
Journal:  Dig Dis Sci       Date:  1985-09       Impact factor: 3.199

6.  Plasma levels of parent drug and metabolites in the intravenous aminopyrine breath test.

Authors:  U Breyer-Pfaff; M Harder; E H Egberts
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.